Evidence
Liver Int. 2024 Apr 18. doi: 10.1111/liv.15946. Online ahead of print.
ABSTRACT
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common paediatric liver disease. Latinos have high MASLD risk due to 50% prevalence of GG genotype of PNPLA3. Our primary aim was to evaluate associations between dietary carbohydrates/sugars and liver stiffness in Latino adolescents with obesity. Our secondary aim was to examine effect modification by (a) PNPLA3 genotype or (b) liver disease severity. Data were obtained from 114 Latino adolescents with obesity involved in two prior studies. No associations were seen between dietary carbohydrates/sugars and liver stiffness in the group as a whole. In subjects with GG genotype of PNPLA3, total sugar, fructose, sucrose, and glucose were associated with liver stiffness. Positive relationships between carbohydrate, total sugar, and sucrose and liver stiffness were stronger in those with MASLD and fibrosis compared to those with healthy livers and MASLD without fibrosis.
PMID:38634702 | DOI:10.1111/liv.15946
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
🌐 90 Days
VR Related Evidence Matrix
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Metabolic disease and the liver: A review
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- COVID-19 in Individuals with Chronic Liver Diseases
- The double roles of T cell-mediated immune response in the progression of MASLD
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- PNPLA3 Genotype and Dietary Fat Modify Concentrations of Plasma and Fecal Short Chain Fatty Acids and Plasma Branched-Chain Amino Acids
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- The Global Epidemic of Metabolic Fatty Liver Disease
- Nonalcoholic Fatty Liver Disease and Continuous Metabolic Syndrome in Adolescents with Overweight/Obesity
- Occult liver disease: a multinational perspective
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- Therapeutic potential of oleanolic acid in liver diseases
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- ALT Poorly Predicts Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis as Determined by Vibration-Controlled Transient Elastography in Adult National Health and Nutrition Examination Survey 2017-2018: ALT Poorly Predicts NAFLD and…
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants
- Dietary pattern associated with non-alcoholic fatty liver disease (NAFLD) in non-diabetic adult patients: A case control study
- Dietary pattern associated with non-alcoholic fatty liver disease (NAFLD) in non-diabetic adult patients: A case control study
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study
- Liver involvement in presence of heart disease and heart involvement in presence of liver disease: a conundrum
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional Study
- Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation
- Ocular manifestations of liver disease: an important diagnostic aid
- Ocular manifestations of liver disease: an important diagnostic aid
- COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Severe Acute Liver Injury: First Manifestation of Systemic Lupus Erythematosus
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Metabolic Muddle. MASLD and MASH on the Horizon
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity
- The Effects of Synbiotics on the Liver Steatosis, Inflammation, and Gut Microbiome of Metabolic Dysfunction-associated Liver Disease Patients-Randomized trial
- High red meat consumption among PNPLA3 polymorphism carriers is associated with NAFLD in a multi-center cross-sectional study
Evidence Blueprint
Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
🌐 365 Days
VR Related Evidence Matrix
- Endotoxin biomarkers, hepatic fat fraction, liver volume and liver stiffness among adolescents at high-risk for non-alcoholic fatty liver disease: The HEROES study
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Review of paediatric obesity and non-alcoholic fatty liver disease-A focus on emerging non-pharmacologic treatment strategies
- Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Metabolic disease and the liver: A review
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Fatty liver disease's renaming impacts on drug clinical trials
- COVID-19 in Individuals with Chronic Liver Diseases
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
- Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Persistent organic pollutants associate with liver disease in a Finnish general population sample
- IL-6 trans-signaling is increased in diabetes, impacted by glucolipotoxicity and associated with liver stiffness and fibrosis in fatty liver disease
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis
- Combined effect of PNPLA3 rs738409 and UGT1A1 rs10929303 gene polymorphisms on nonalcoholic fatty liver disease in children
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- PNPLA3 Genotype and Dietary Fat Modify Concentrations of Plasma and Fecal Short Chain Fatty Acids and Plasma Branched-Chain Amino Acids
- Different dietary carbohydrate component intakes and long-term outcomes in patients with NAFLD: results of longitudinal analysis from the UK Biobank
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with non-alcoholic fatty liver disease
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance
- Usefulness of two-dimensional shear wave elastography in the assessment of non-alcoholic fatty liver disease in children and adolescents
- National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Liver health and the interplay between obesity, alcohol and bariatric surgery
- Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study
- Relationship of ferritin and hepcidin with disease severity in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus
- Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study
- Risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease: a systematic review and meta-analysis
- The Global Epidemic of Metabolic Fatty Liver Disease
- Nonalcoholic Fatty Liver Disease and Continuous Metabolic Syndrome in Adolescents with Overweight/Obesity
- The pathophysiology of MASLD: an immunometabolic perspective
- Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease
- Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism
- Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism
- Organ dysfunction and failure in liver disease
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review